The results here also suggest the potential to employ FUS+TRAIL in combination with other therapeutic regimens, such as Temozolomide, to enhance the anti‐cancer effects to treat GBM to create a three‐component therapeutic approach.[23, 121]. The gene discussed is TNFSF10; the disease is glioblastoma.